CA3045070A1 - Application of epigenetic chromsomal interactions in cancer diagnostics - Google Patents
Application of epigenetic chromsomal interactions in cancer diagnostics Download PDFInfo
- Publication number
- CA3045070A1 CA3045070A1 CA3045070A CA3045070A CA3045070A1 CA 3045070 A1 CA3045070 A1 CA 3045070A1 CA 3045070 A CA3045070 A CA 3045070A CA 3045070 A CA3045070 A CA 3045070A CA 3045070 A1 CA3045070 A1 CA 3045070A1
- Authority
- CA
- Canada
- Prior art keywords
- chromosome
- sequence
- nucleic acids
- interaction
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/30—Phosphoric diester hydrolysing, i.e. nuclease
- C12Q2521/301—Endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/50—Other enzymatic activities
- C12Q2521/501—Ligase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2523/00—Reactions characterised by treatment of reaction samples
- C12Q2523/10—Characterised by chemical treatment
- C12Q2523/101—Crosslinking agents, e.g. psoralen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/50—Detection characterised by immobilisation to a surface
- C12Q2565/501—Detection characterised by immobilisation to a surface being an array of oligonucleotides
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428893P | 2016-12-01 | 2016-12-01 | |
| US62/428,893 | 2016-12-01 | ||
| PCT/GB2017/053615 WO2018100381A1 (en) | 2016-12-01 | 2017-11-30 | Application of epigenetic chromsomal interactions in cancer diagnostics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3045070A1 true CA3045070A1 (en) | 2018-06-07 |
Family
ID=60702831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3045070A Pending CA3045070A1 (en) | 2016-12-01 | 2017-11-30 | Application of epigenetic chromsomal interactions in cancer diagnostics |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11560597B2 (enExample) |
| EP (2) | EP3548633B1 (enExample) |
| JP (2) | JP2019535295A (enExample) |
| KR (1) | KR102481242B1 (enExample) |
| CN (1) | CN110234769B (enExample) |
| AU (1) | AU2017367245B2 (enExample) |
| CA (1) | CA3045070A1 (enExample) |
| ES (1) | ES2971286T3 (enExample) |
| MY (1) | MY190153A (enExample) |
| PL (1) | PL3548633T3 (enExample) |
| TW (1) | TWI865427B (enExample) |
| WO (1) | WO2018100381A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2626699B (en) * | 2019-05-08 | 2024-11-20 | Oxford BioDynamics PLC | Chromosome Conformation Markers of Prostate Cancer and Lymphoma |
| GB202008269D0 (en) * | 2020-06-02 | 2020-07-15 | Oxford Biodynamics Ltd | Detecting a chromosome marker |
| CN118506860B (zh) * | 2024-07-18 | 2024-10-08 | 广州女娲生命科技有限公司 | 药物表观遗传安全性评价的检测分析方法及系统 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006264564B2 (en) * | 2005-07-04 | 2012-04-19 | Erasmus University Medical Center | Chromosome conformation capture-on-chip (4c) assay |
| GB0603251D0 (en) * | 2006-02-17 | 2006-03-29 | Isis Innovation | DNA conformation |
| CN101688237A (zh) * | 2007-01-11 | 2010-03-31 | 伊拉兹马斯大学医疗中心 | 环状染色体构象捕获（4c） |
| US20090117076A1 (en) * | 2007-11-01 | 2009-05-07 | Chen Lei L | Methods For Treating Tumor Cells |
| GB0810051D0 (en) * | 2008-06-02 | 2008-07-09 | Oxford Biodynamics Ltd | Method of diagnosis |
| US9434985B2 (en) * | 2008-09-25 | 2016-09-06 | University Of Massachusetts | Methods of identifying interactions between genomic loci |
| WO2010059742A1 (en) * | 2008-11-18 | 2010-05-27 | Collabrx, Inc. | Individualized cancer treatment |
| AU2011274642B2 (en) * | 2010-07-09 | 2015-05-21 | Cergentis B.V. | 3-d genomic region of interest sequencing strategies |
| CA2828099A1 (en) * | 2011-02-24 | 2012-08-30 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-erbb3 agents |
| EP2710146A2 (en) * | 2011-05-18 | 2014-03-26 | Life Technologies Corporation | Chromosome conformation analysis |
| US20150182490A1 (en) * | 2012-06-26 | 2015-07-02 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| CN102827935B (zh) * | 2012-08-29 | 2013-12-18 | 北京大学人民医院 | 定量检测FIP1L1-PDGFRA融合基因mRNA水平的试剂盒 |
| GB201320351D0 (en) * | 2013-11-18 | 2014-01-01 | Erasmus Universiteit Medisch Ct | Method |
| JP2018527016A (ja) | 2015-06-24 | 2018-09-20 | オックスフォード バイオダイナミックス リミテッド | 染色体相互作用の検出 |
| US11339442B2 (en) * | 2015-12-14 | 2022-05-24 | The General Hospital Corporation | Methods of detecting insulator dysfunction and oncogene activation for screening, diagnosis and treatment of patients in need thereof |
| GB201608000D0 (en) | 2016-05-06 | 2016-06-22 | Oxford Biodynamics Ltd | Chromosome detection |
-
2017
- 2017-11-30 ES ES17817030T patent/ES2971286T3/es active Active
- 2017-11-30 JP JP2019528462A patent/JP2019535295A/ja active Pending
- 2017-11-30 AU AU2017367245A patent/AU2017367245B2/en active Active
- 2017-11-30 US US16/465,133 patent/US11560597B2/en active Active
- 2017-11-30 EP EP17817030.4A patent/EP3548633B1/en active Active
- 2017-11-30 KR KR1020197019088A patent/KR102481242B1/ko active Active
- 2017-11-30 CA CA3045070A patent/CA3045070A1/en active Pending
- 2017-11-30 WO PCT/GB2017/053615 patent/WO2018100381A1/en not_active Ceased
- 2017-11-30 EP EP23217260.1A patent/EP4357463A3/en active Pending
- 2017-11-30 PL PL17817030.4T patent/PL3548633T3/pl unknown
- 2017-11-30 MY MYPI2019002870A patent/MY190153A/en unknown
- 2017-11-30 CN CN201780085308.2A patent/CN110234769B/zh active Active
- 2017-12-01 TW TW106142279A patent/TWI865427B/zh active
-
2022
- 2022-10-28 US US18/050,795 patent/US20230082230A1/en active Pending
- 2022-11-16 JP JP2022183117A patent/JP7579003B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3548633A1 (en) | 2019-10-09 |
| JP2023027076A (ja) | 2023-03-01 |
| JP2019535295A (ja) | 2019-12-12 |
| AU2017367245B2 (en) | 2020-09-24 |
| KR20190086569A (ko) | 2019-07-22 |
| JP7579003B2 (ja) | 2024-11-07 |
| TW201842190A (zh) | 2018-12-01 |
| NZ753716A (en) | 2024-05-31 |
| US11560597B2 (en) | 2023-01-24 |
| EP3548633C0 (en) | 2024-01-24 |
| AU2017367245A1 (en) | 2019-06-06 |
| EP4357463A2 (en) | 2024-04-24 |
| MY190153A (en) | 2022-03-31 |
| WO2018100381A1 (en) | 2018-06-07 |
| US20190338367A1 (en) | 2019-11-07 |
| ES2971286T3 (es) | 2024-06-04 |
| TWI865427B (zh) | 2024-12-11 |
| PL3548633T3 (pl) | 2024-04-02 |
| EP4357463A3 (en) | 2024-07-17 |
| CN110234769B (zh) | 2024-06-07 |
| EP3548633B1 (en) | 2024-01-24 |
| US20230082230A1 (en) | 2023-03-16 |
| KR102481242B1 (ko) | 2022-12-23 |
| CN110234769A (zh) | 2019-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230082230A1 (en) | Application of epigenetic chromosomal interactions in cancer diagnostics | |
| JP7005596B2 (ja) | 乳がんに関連する染色体相互作用の検出 | |
| JP7631400B2 (ja) | 遺伝子調節 | |
| WO2022148958A1 (en) | Analysis method | |
| US11535893B2 (en) | Typing method | |
| HK40111334A (en) | Application of epigenetic chromsomal interactions in cancer diagnostics | |
| KR20220007132A (ko) | 전립선암 및 림프종의 염색체 형태 마커 | |
| TW202302862A (zh) | 染色體交互作用標記物 | |
| CN111349691A (zh) | Egfr基因缺失突变检测用组合物、试剂盒及检测方法 | |
| HK40013967A (en) | Application of epigenetic chromsomal interactions in cancer diagnostics | |
| HK40013967B (en) | Application of epigenetic chromsomal interactions in cancer diagnostics | |
| JP2023545364A (ja) | 疾患マーカー | |
| CN116507740A (zh) | 检测作为用于纤维化例如硬皮病的标志物的染色体构象 | |
| CN117795098A (zh) | 染色体相互作用标志物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20221122 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240731 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241202 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241202 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241202 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250108 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250221 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250221 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251024 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260112 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260601 |